Merck says FDA again declines to approve Bridion, needs more data

April 28 (Reuters) - Merck & Co on Tuesday said the U.S. Food and Drug Administration has again declined to approve Bridion, its drug to reverse the effects of muscle relaxants used in surgery, until the agency receives more data on allergic reactions to the product.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.